11/05/2026
Value in healthcare is not only about extending life, but improving the life extended.
In health economics, value is commonly operationalized through the Quality-Adjusted Life Year (QALY), a metric thatintegrates survival duration with health-related quality-of-life weights into a single outcome. This enables decision-makers to assess therapies not only by how long patients live, but by how well they live.
The National Institute for Health and Care Excellence uses cost per QALY gained as a central criterion in its technologyappraisals, while the Institute for Clinical and Economic Review incorporates QALY-based analyses within its valueassessment framework, including long-term and budget impact considerations.
Within this model, Patient-Reported Outcomes are critical inputs. The U.S. Food and Drug Administration defines PROsas direct reports from patients about how they feel or function without external interpretation. Because these measuresinform health-state utility values, they can influence cost-effectiveness results and, ultimately, reimbursementconclusions.
For pharmaceutical strategy, this is decisive. Survival gains matter. But validated improvements in quality of life canshape HTA outcomes, pricing discussions, and long-term access.
In value-based systems, survival is quantified in years. Reimbursement decisions are increasingly shaped by the qualityof those years.